The Clinical Coding and Schedule Development (CCSD) group develop and maintains procedural and diagnostics nomenclature for private payers in England. New procedure codes concern mastectomy and immediate reconstruction of the breast, coronary intravascular lithotripsy, angioplasty, insertion of a stent, portal vein embolization, and others and diagnostic codes for tests for primary hyperoxaluria panel, myeloid panel, and hereditary angioedema. The codes are introduced with a recommended adoption date being the 1st of August 2019. The documents also contain a list of textual changes in codes and an updated list of unacceptable combinations of codes.
The CCSD Group has approved the following procedure codes for publication to the CCSD Schedule in May 2019 with a recommended adoption date being the 1st of August 2019:
- Extracapsular dissection of the parotid tumor (F4500)
- 2 stage revision of total shoulder replacement for infection - the first stage
- (W5031)
- 2 stage revision of total shoulder replacement for infection - second stage (W5032)
- Transcervical radiofrequency ablation of uterine fibroids under image guidance (Q1720)
- Repair of femoral, inguinal or umbilical hernia requiring removal of previously inserted mesh (T2790)
- Convergent procedure and catheter ablation for persistent atrial fibrillation (K5735)
- Mastectomy and immediate reconstruction of the breast using expandable prosthesis - bilateral (B3042)
- Mastectomy and immediate reconstruction of the breast using fixed prosthesis – bilateral (B3043)
- Coronary intravascular lithotripsy +/- angioplasty +/- insertion of stent (K7510)
- Intracavernosal injection (N3240)
- Portal vein embolization (as sole procedure) (XR363)
See full details here.
The CCSD Group has approved the following diagnostic codes for publication to the CCSD Schedule in May 2019 with a recommended adoption date being the 1st of August 2019:
- Hereditary Angioedema (HAE) SERPING 1 gene (0635G)
- Primary Hyperoxaluria Panel (3547G)
- Myeloid Panel (3018G)
See full details here.
Subscribe to our newsletter delivered every second week not to miss important reimbursement information.